彭布罗利珠单抗
医学
安慰剂
临床试验
肿瘤科
内科学
免疫疗法
替代医学
癌症
病理
作者
Vernon K. Sondak,Nikhil I. Khushalani
出处
期刊:Lancet Oncology
[Elsevier BV]
日期:2019-06-17
卷期号:20 (8): 1037-1039
被引量:10
标识
DOI:10.1016/s1470-2045(19)30312-2
摘要
There were high expectations for combining the IDO1 inhibitor epacadostat with pembrolizumab, an anti-PD-1 antibody, based on promising data from a phase 1 trial,1 which involved just 22 patients with melanoma (12 of whom responded) treated with various doses of epacadostat. The placebo-controlled phase 3 ECHO-301/KEYNOTE-252 trial done by Georgina V Long and colleagues,2 published in The Lancet Oncology, involving 706 patients with melanoma, was launched to assess if the combination of epacadostat 100 mg orally twice per day with pembrolizumab 200 mg intravenously every 3 weeks was better than pembrolizumab alone.
科研通智能强力驱动
Strongly Powered by AbleSci AI